Rimegepant, Glofitamab, and CAR-T Cells for Resistant Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of three treatments—rimegepant, glofitamab, and CAR-T cell therapy—for patients with large B-cell lymphoma that has stopped responding to previous treatments. The goal is to see if this combination can help control the cancer and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have large B-cell lymphoma that came back or didn't respond to at least one prior treatment, including standard chemotherapy and anti-CD20 antibody therapy
- Your lymphoma has at least one high-risk feature, such as spread to organs outside lymph nodes, bulky tumors, or specific genetic changes (TP53 abnormality)
- You are 18 years or older and in good enough general health (ECOG performance status 0–2)
- Your bone marrow, liver, kidneys, lungs, and heart are working well enough for treatment
- You have not had a stem cell transplant or organ transplant in the past
- You agree to use effective birth control during the study if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.
This trial tests combining two therapies—a CAR T-cell treatment and an antibody drug called glofitamab—for people with large B-cell lymphoma that has come back or not responded to initial treatment and has certain high-risk features.
This trial tests a new combination treatment for patients with large B-cell lymphoma who did not respond well to CAR-T cell therapy (a type of immunotherapy). The study uses tumor testing to guide which drugs to use, aiming to help patients whose cancer has stopped responding or is growing again.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This study is testing a new combination of two treatments—glofitamab (a targeted antibody) and CAR-T cell therapy—for people with relapsed or refractory large B-cell lymphoma. It is for patients who have not responded to or have relapsed after at least one prior treatment and have certain high-risk features.
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
Hear when a new Relapsed/Refractory Large B-cell Lymphoma (LBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.